AstraZeneca (NYSE:AZN) announced changes in its top management team in an official statement released today.The crucial post of president of research and development, currently held by the departing Martin Mackay, is to be eliminated and replaced by three individuals responsible for different pharmaceutical segments.
In addition, the company's top sales executive, Executive Vice President of Global Commercial Tony Zook, is to leave the company. His position will also be eliminated and carried out by three managers, each responsible for a different commercial region -- North America, Europe, and international.
The shakeup comes several months after the appointment of current CEO Pascal Soriot, who took his position last summer following the sudden retirement of his predecessor, David Brennan.
Eric Volkman and The Motley Fool have no position in AstraZeneca. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Better Stock: Procter & Gamble Co (PG) vs. Unilever NV (UN)
It's a virtual tie of solid dividend-payers. But this one factor gives one a winning edge.
Why the Apple Inc. iPhone X Isn't Doing as Well as Hoped in China
The answer might surprise you.
3 Signs You're Better Off Delaying Retirement
If you're coping with any of the issues below, then retiring now is probably a bad idea.